fda glp-1 warning letters october 2025 issued 25 to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA AI Warning Letter (Purolea):

BPC-157 accelerates tendon-to-bone and muscle-to-tendon reattachment, while TB-500 promotes myofiber regeneration and fibroblast migration

Our medically supervised weight loss treatment enhances fat metabolism, giving you the extra support you need on your journey to better health

They feel like they can return to full training

The parenteral GLP-1 receptor agonist market is projected to grow by $47,567 million, the GLP-1 receptor agonists for hospitals market by $43,598 million, and the semaglutide-based GLP-1 receptor agonist market by $38,238 million over the next five years from 2025 to 2030

All prices are accurate at the time of publication

Serving size: 1 capsule